The United Kingdom and the United States have agreed to a landmark commercial pact that will preserve no levies on UK pharmaceutical products going into the American market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has agreed to raise spending on pharmaceuticals through the NHS. This pledge guarantees that tariffs on these key goods will stay at zero for a period of 36 months.
This deal is in response to previous threats to dramatically increase import taxes on patented pharmaceutical products, with increases discussed up to one hundred percent.
"This arrangement between the Britain reinforces the worldwide climate for innovative medicines and introduces long-overdue equity to U.S.–U.K. medicine commerce," a statement declared.
Economic Impact
Medicines are one of the UK's biggest goods shipped to the US, which is clearly the biggest destination for large British pharmaceutical firms.
Export figures indicate that in the one-year period to the end of September, the UK sold drugs worth billions to the US. This figure made up 17.4% of all goods exports in that timeframe.
"This guarantee safeguards jobs, boosts investment and facilitates the UK to become a international leader for life sciences," a minister stated.
Key British Pledges
The deal involves several notable changes from the British government:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a goal to double overall NHS spending on drugs from 0.3% of the national economy to 0.6% over the coming ten years.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. Previously, rebates exceeded 20%.
Recent Tensions
This agreement comes amid a ongoing tension between the pharmaceutical industry and the ministers over spending levels and regulatory access.
The disagreement were heightened by arguments that US customers were charged a premium for the same drugs than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been pledged toward US facilities.
One official publicly accepted that the NHS had to spend more on medicines, noting that its spending on drugs had shrunk as a share of its overall budget over the last ten years.
